EUVIMEDEUVIMED entdecken
Crossref

Novel hydrazide‐hydrazone containing 1,2,4‐triazole as potent inhibitors of antiapoptotic protein Bcl‐xL: Synthesis, biological evaluation, and docking studies

Ebru Didem Kuran, Burcu Uner, Muhammet Emin Cam, Nuray Ulusoy-Guzeldemirci

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202400562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Ebru Didem Kuran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İstanbul University, İstanbul, Turkey. Hauptthemen laut MEDLINE: bcl-X Protein, Triazoles, Hydrazones, Molecular Docking Simulation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Istanbul University Scientific Research, Scientific and Technological Research Council of Turkey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study describes the synthesis and characterization of a series of novel hydrazide‐hydrazone derivatives containing a 1,2,4‐triazole ring. The compounds were characterized using various spectroscopic techniques, such as FT‐IR, 1 H‐NMR, 13 C‐NMR, HRMS, and elemental analysis. The antiproliferative activity of the synthesized compounds was evaluated against a panel of human cancer cell lines (HCT‐116, HepG‐2, KLN205, LTPA, U138, and SW620) and healthy cell lines (HSkMC and iPSCs). Among the compounds tested, compounds 4 , 5p , 5r , and 5s showed the highest effectiveness in inhibiting the growth of cancer cells with Bcl‐xL inhibitory concentration (IC 50 ) values. These compounds further demonstrated selective cytotoxicity against the Bcl‐xL‐dependent lymphoma cell line (DBs). Molecular docking studies were also performed to investigate the potential binding interactions of compounds 4 , 5p , 5r , and 5s with the active site of Bcl‐xL (PDB ID: 7LH7, 1.4 Å). Mechanistic studies revealed that compounds 4 , 5r , and 5s induced apoptosis predominantly through the intrinsic mitochondrial pathway, while compound 5p exhibited a distinct cell cycle arrest profile, impacting both the S and G2/M phases. Western blot analysis suggested that these compounds may downregulate cyclin expression, thereby blocking its association with Bcl‐xL. Overall, these results demonstrate the potential of these novel hydrazide‐hydrazone derivatives as anticancer agents with activity comparable or superior to doxorubicin and 5‐fluorouracil.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

bcl-X ProteinTriazolesHydrazonesMolecular Docking SimulationAntineoplastic AgentsApoptosisCell ProliferationHumansStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugCell Line, TumorHydrazines

Stichwörter der Autor:innen

1,2,4‐triazoleBcl‐xLcytotoxicityhydrazide hydrazonessynthesis

Substanzen

bcl-X ProteinTriazolesHydrazonesAntineoplastic AgentsBCL2L1 protein, human1,2,4-triazoleHydrazines

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İstanbul University, İstanbul, Turkey.
  • Graduate School of Health Sciences, İstanbul University, İstanbul, Turkey.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İstanbul Kent University, İstanbul, Turkey.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, İstanbul Kent University, İstanbul, Turkey.
  • Department of Pharmaceutical and Administrative Sciences, University of Health Science and Pharmacy in St. Louis, St. Louis, Missouri, USA.
  • Department of Anesthesiology, Center for Clinical Pharmacology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

Förderung

  • Istanbul University Scientific Research
  • Scientific and Technological Research Council of Turkey

Zitieren

APA

Kuran, E. D., Uner, B., Cam, M. E., & Ulusoy-Guzeldemirci, N. (2024). Novel hydrazide‐hydrazone containing 1,2,4‐triazole as potent inhibitors of antiapoptotic protein Bcl‐xL: Synthesis, biological evaluation, and docking studies. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400562

Vancouver

Kuran ED, Uner B, Cam ME, Ulusoy-Guzeldemirci N. Novel hydrazide‐hydrazone containing 1,2,4‐triazole as potent inhibitors of antiapoptotic protein Bcl‐xL: Synthesis, biological evaluation, and docking studies. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400562

BibTeX
@article{Kuran2024,
  author = {Kuran, Ebru Didem and Uner, Burcu and Cam, Muhammet Emin and Ulusoy-Guzeldemirci, Nuray},
  title = {Novel hydrazide‐hydrazone containing 1,2,4‐triazole as potent inhibitors of antiapoptotic protein Bcl‐xL: Synthesis, biological evaluation, and docking studies},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202400562}
}
Kostenlos starten →